Biomoda Honors Veterans With Pledge To Lower Rate Of Lung Cancer

Main Category: Lung Cancer
Also Included In: Cancer / Oncology
Article Date: 10 Nov 2009 - 5:00 PST

email to a friend   printer friendly   view / write opinions

Biomoda, Inc. (OTCBB: BMOD) President John Cousins called upon governors in all 50 states to proclaim November "Lung Cancer Awareness Month" on behalf of veterans and their families and pledged to continue the company's focus on veterans in the research, development and commercialization of diagnostic technology for detection of early-stage lung cancer.

"America can truly honor its 25 million veterans by making a commitment to fight lung cancer. Veterans have a 25 percent higher risk than the general population of developing lung cancer and dying from the disease," Cousins said. "The men and women who served our country deserve nationwide recognition that lung cancer is a significant threat to their health, and they deserve our commitment to lower their risk with early detection and awareness."

Based on a molecular marker technology originally developed at Los Alamos National Laboratory, Biomoda's CyPath® assay is expected to improve the survivability of lung cancer through early detection and treatment. "As we prepare to expand our clinical trial to multiple sites across the country, we will continue to focus research on lowering the cancer burden carried by veterans, and we urge others to do the same," Cousins said.

Cousins called upon the nation's governors to issue proclamations declaring November "Lung Cancer Awareness Month" on Veterans Day. He applauded The Lung Cancer Alliance and its nationwide campaign to obtain proclamations from all 50 states. "The Lung Cancer Alliance continues its service to our veterans by providing the means for every governor to join in the fight and issue a proclamation that highlights the dismal statistics our veterans face and gives hope that those statistics soon will change for the better."

Biomoda's first product, an in-vitro test for the detection of early-stage lung cancer, is currently in Phase II clinical trials. Study volunteers provide deep-lung sputum samples to be screened for cancer cells with the CyPath® assay in the Biomoda lab. Results are compared to CT scans and Pap stains read by independent radiologists and cytopathologists, respectively, to confirm accuracy.

Source
Biomoda